Lexaria Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Net Income	-7.74	-11.91	-5.81	-6.71	-7.38	-4.19
Depreciation & Amortization	0.08	0.09	0.08	0.15	0.1	0.11
Stock-Based Compensation	0.37	0.86	0.49	0.17	1.95	1.28
Other Adjustments	0.28	0.32	0.17	0.37	0.8	-1.26
Change in Receivables	0.31	-0.21	-0.04	0.03	-0.14	0.19
Changes in Inventories	-	-	-	0.04	-0	0.1
Changes in Accounts Payable	-1.11	0.4	0.83	0.09	0.05	0.01
Changes in Unearned Revenue	0	-0	0	-	-	-0.04
Changes in Other Operating Activities	0.39	0.02	-0.69	-0.01	-0.26	-0.19
Operating Cash Flow	-7.43	-10.45	-4.96	-5.88	-4.88	-3.99
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-0.04	-0.02	-0.04	-0.03	-0.05	-
Sale of Property, Plant & Equipment	-	-	-	-	-	0.27
Purchases of Intangible Assets	-0.06	-0.08	-0.15	-0.14	-0.13	-0.08
Purchases of Investments	-0.07	-0.14	-	-	-	-
Investing Cash Flow	-0.24	-0.24	-0.19	-0.17	-0.18	0.19
Long-Term Debt Issued	-	-	-	-	-	-0.02
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-0.02
Issuance of Common Stock	6.52	6.05	10.32	1.59	-	13.49
Net Common Stock Issued (Repurchased)	6.52	6.05	10.32	1.59	-	13.49
Other Financing Activities	-	-	-	-	-0.04	-0.04
Financing Cash Flow	6.52	6.05	10.32	1.59	-0.04	13.42
Foreign Exchange Rate Adjustments	0.03	-0.05	-0.02	-	-	-
Net Cash Flow	-1.12	-4.7	5.15	-4.46	-5.1	9.62
Free Cash Flow	-7.47	-10.48	-5	-5.91	-4.93	-3.99
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-3848.61%	-1483.88%	-1077.38%	-2614.84%	-1929.75%	-552.02%
Free Cash Flow Per Share	-0.33	-0.58	-0.40	-0.89	-0.84	-0.91
Levered Free Cash Flow	-8.42	-11.43	-5.62	-6.44	-7.43	-4.06
Unlevered Free Cash Flow	-8.39	-11.41	-5.58	-6.31	-6.78	-5.7

SEC Filings: 10-K · 10-Q